Advent of advanced technologies for treating cardiovascular disease is intensifying the size of cardiac pacing leads the market

 

Cardiac Pacing Leads Market

The purpose of a cardiac pacing lead is to get the pulse rate of the heart up to a certain level. Usually, the patient has to be in a coma or at least out of deep, cardiac sleep to have their cardiac activity measured. Once they are in a comatose state then a cardiac pacing lead can be used to start or continue the pumping action in the heart

Increasing incidences of cardiovascular diseases around the globe are driving the growth of the cardiac pacing leads the market. According to the U.S. Department of Health & Human Services, about 655,000 Americans die from heart disease each year—that’s 1 in every 4 deaths. Coronary heart disease is the most common type of heart disease, killing 365,914 people in 2017. The economic burden of the disease is propelling the growth of the cardiac pacing leads market. Recently the outbreak of novel coronavirus has severely affected the patients suffering from cardiac problems. Thus this has again raised the demand for cardiac pacing leads. Furthermore, the growing demand for various pacemaker implantations for enhancing patient outcomes is further anticipated to accelerate the growth of the market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high presence of the geriatric population which is increasing prevalence of the cardiovascular disease. According to the Urban Institute, the number of Americans ages 65 and older will more than double over the next 40 years, reaching 80 million in 2040. The number of adults ages 85 and older, the group most often needing help with basic personal care, will nearly quadruple between 2000 and 2040.

Key Developments:

1.      In May 2020, Medtronic plc announced results from late-breaking clinical trials evaluating the MyCareLink Heart™ mobile app and the Micra® Transcatheter Pacing System (TPS), products that provide needed care for patients and optimal management of their symptoms – while reducing potential exposure between patients and their clinicians.

2.      In March 2017, BIOTRONIK has launched its smallest and lightest mr-conditional pacemakers and a new range of Quadripolar CRT-Ps in Europe

3.      In January 2020, Medtronic has won FDA approval for its Micra AV — greatly expanding the number of people who could potentially benefit from leadless pacemaker technology

4.      In February 2020, Abbott has announced it has received CE Mark for the new Gallant™ implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

Pressure Bandages Market : Global Industry Analysis and Opportunity Assessment

Botanical and Plant Derived Drugs Market by Source,Dosage - Global Industry Analysis,Size,Share